DMD and Duchenne muscular dystrophy: Orna Therapeutics company, established by Aderson et al., has reported their recent progress in treating Duchenne Muscular Dystrophy (DMD) at ASGCT 2022 through circRNA‐mediated expression of dystrophin, addressing a challenge posed by protein therapy due to the relatively high molecular weight of dystrophin.